Back to results

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Primary Purpose

Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma

Status

Withdrawn

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

Cyclophosphamide

Laboratory Biomarker Analysis

Oregovomab

About this trial

This is an interventional treatment trial for Fallopian Tube Carcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Criteria:

Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal adenocarcinoma
Histologic documentation of the original primary tumor is required via pathology report
FIGO stage III-IV disease
Must have received 5-8 courses of front-line taxane- and platinum-based chemotherapy OR treatment on a first-line Gynecologic Oncology Group (GOG) protocol AND must have become clinically free of disease as measured by serum CA-125 level, CT scan, or physical examination
Must have documentation of a defined progression-free interval after front-line therapy, as measured from the date of initiation of front-line chemotherapy to the date of initiation of second-line chemotherapy
Relapsed disease (prior to starting second-line chemotherapy), defined by 1 of the following: doubling of serum CA-125 level confirmed by measurements taken 1 week apart (CA-125 level should have been elevated to at least double the level seen during the first complete response); identification of a new lesion by CT/MRI scan or physical examination
Must have completed 5-8 courses of second-line taxane- and platinum-based chemotherapy 4-8 weeks ago
Second-line chemotherapy must not have been started before clear evidence of disease recurrence was documented using RECIST criteria
Achieved complete clinical response to second-line chemotherapy with no symptoms suggestive of persistent disease, defined by the following: normal physical examination; reduction from the peak serum CA-125 level to a normal value of >= 5 U/mL; complete regression of recurrent lesions by CT scan of the abdomen/pelvis
No low malignant potential tumors or noninvasive disease
GOG performance status 0-1
ANC >= 1,500/mm^3
Platelet count >= 100,000/mm^3
Hemoglobin >= 8.0 g/dL
Creatinine =< 1.5 times upper limit of normal (ULN)
Bilirubin =< 1.5 times ULN
AST =< 2.5 times ULN
Alkaline phosphatase =< 2.5 times ULN
No known allergy to murine proteins, documented anaphylactic reaction to any drug, or intolerance to cyclophosphamide
No active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, or ankylosing spondylitis)
No recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia
No acquired, hereditary, or congenital immunodeficiencies
No other concurrent uncontrolled diseases
No contraindications to pressor agents
No other invasive malignancies within the past 5 years, except nonmelanoma skin cancer
No prior cancer treatment that would contraindicate study therapy
No concurrent chronic treatment with immunosuppressive drugs (e.g., cyclosporine, adrenocorticotropic hormone [ACTH], or systemic corticosteroids)

Sites / Locations

Gynecologic Oncology Group

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arm I

Arm II

Arm Description

Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity.

Patients undergo DTH skin testing and receive oregovomab as in arm I.

Outcomes

Primary Outcome Measures

Frequency and severity of adverse events as assessed by NCI CTCAE v3.0

Serum human anti-murine antibodies (HAMA) as assessed by enzyme-linked immunosorbent assay (ELISA)

Secondary Outcome Measures

Duration of time from first response to first recurrence

A descriptive analysis of the bivariate distribution of each patient's first and second response duration will be conducted.

Duration of time from second response to second recurrence

A descriptive analysis of the bivariate distribution of each patient's first and second response duration will be conducted.

Frequency and magnitude of patients who have a delayed-type hypersensitivity (DTH) response to oregovomab, tetanus, mumps, and Candida as assessed by DTH skin testing

Serum HAMA and anti-idiotype antibodies as assessed by ELISA over the course of treatment

Full Information

NCT ID

NCT00551265

First Posted

October 25, 2007

Last Updated

July 12, 2017

Sponsor

Gynecologic Oncology Group

Collaborators

National Cancer Institute (NCI)

1. Study Identification

Unique Protocol Identification Number

NCT00551265

Brief Title

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Official Title

A Randomized Pilot Trial of Consolidation With an Adjuvant Ovarian Cancer Vaccine Oregovomab (Ovarex ®) With/Without Single-Dose Cyclophosphamide After a Complete Clinical Response to Second-Line Taxane/Platinum-Based Therapy to Determine Immune Response and Time to Progression in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Study Type

Interventional

2. Study Status

Record Verification Date

July 2017

Overall Recruitment Status

Withdrawn

Study Start Date

October 2007 (undefined)

Primary Completion Date

January 2009 (Actual)

Study Completion Date

undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Gynecologic Oncology Group

Collaborators

National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary

This randomized clinical trial is studying the side effects of oregovomab and to see how well it works with or without cyclophosphamide in treating patients with stage III or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that responded to second-line chemotherapy. Monoclonal antibodies, such as oregovomab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether oregovomab is more effective when given together with or without cyclophosphamide in treating patients with stage III or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Detailed Description

PRIMARY OBJECTIVES: I. To characterize the nonspecific humoral immune response, as measured by human anti-murine antibodies (HAMA), in patients with stage III or IV ovarian epithelial, fallopian tube, or primary peritoneal adenocarcinoma treated with consolidation therapy comprising adjuvant oregovomab with vs without cyclophosphamide after achieving a complete clinical response to second-line taxane/platinum-based therapy. II. To compare the magnitude of the immune responses in these patients at approximately 14 weeks after the initial treatment. III. To determine the frequency and severity of adverse events, as assessed by NCI CTCAE v3.0, in patients treated with these regimens. SECONDARY OBJECTIVES: I. To characterize the specific humoral immune response, as measured by HAMA and anti-idiotype antibodies, in these patients. II. To assess the treatment emergent cellular immune response, by measuring the delayed-type hypersensitivity response to the anergy panel and to oregovomab as compared to baseline, in these patients. III. To characterize the duration of each patient's first progression-free interval after primary chemotherapy and second progression-free interval after another regimen of chemotherapy. OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo DTH skin testing and receive oregovomab as in arm I. Blood samples are obtained from patients at baseline and at weeks 14 and 38 for immunologic correlative studies. Samples are examined to determine CA-125 levels and human anti-murine antibody (HAMA) and anti-idiotype antibody levels by enzyme-linked immunosorbent assay (ELISA). After completion of study therapy, patients are followed every 3 months for 2 years and then every 6 months for 3 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

0 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Arm I

Arm Type

Experimental

Arm Description

Arm Title

Arm II

Arm Type

Active Comparator

Arm Description

Patients undergo DTH skin testing and receive oregovomab as in arm I.

Intervention Type

Drug

Intervention Name(s)

Cyclophosphamide

Other Intervention Name(s)

(-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719

Intervention Description

Given IV

Intervention Type

Procedure

Intervention Name(s)

Laboratory Biomarker Analysis

Intervention Description

Correlative studies

Intervention Type

Biological

Intervention Name(s)

Oregovomab

Other Intervention Name(s)

B43.13, MoAb B43.13, Monoclonal Antibody B43.13, OvaRex, OvaRex Monoclonal Antibody B43.13

Intervention Description

Given IV

Primary Outcome Measure Information:

Title

Frequency and severity of adverse events as assessed by NCI CTCAE v3.0

Time Frame

Up to 30 days after final treatment

Title

Serum human anti-murine antibodies (HAMA) as assessed by enzyme-linked immunosorbent assay (ELISA)

Time Frame

At approximately 14 weeks after initial treatment

Secondary Outcome Measure Information:

Title

Duration of time from first response to first recurrence

Description

A descriptive analysis of the bivariate distribution of each patient's first and second response duration will be conducted.

Time Frame

Up to 5 years

Title

Duration of time from second response to second recurrence

Description

A descriptive analysis of the bivariate distribution of each patient's first and second response duration will be conducted.

Time Frame

Up to 5 years

Title

Frequency and magnitude of patients who have a delayed-type hypersensitivity (DTH) response to oregovomab, tetanus, mumps, and Candida as assessed by DTH skin testing

Time Frame

Baseline to 14 weeks

Title

Serum HAMA and anti-idiotype antibodies as assessed by ELISA over the course of treatment

Time Frame

At approximately 14 weeks after initial treatment

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Criteria: Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal adenocarcinoma Histologic documentation of the original primary tumor is required via pathology report FIGO stage III-IV disease Must have received 5-8 courses of front-line taxane- and platinum-based chemotherapy OR treatment on a first-line Gynecologic Oncology Group (GOG) protocol AND must have become clinically free of disease as measured by serum CA-125 level, CT scan, or physical examination Must have documentation of a defined progression-free interval after front-line therapy, as measured from the date of initiation of front-line chemotherapy to the date of initiation of second-line chemotherapy Relapsed disease (prior to starting second-line chemotherapy), defined by 1 of the following: doubling of serum CA-125 level confirmed by measurements taken 1 week apart (CA-125 level should have been elevated to at least double the level seen during the first complete response); identification of a new lesion by CT/MRI scan or physical examination Must have completed 5-8 courses of second-line taxane- and platinum-based chemotherapy 4-8 weeks ago Second-line chemotherapy must not have been started before clear evidence of disease recurrence was documented using RECIST criteria Achieved complete clinical response to second-line chemotherapy with no symptoms suggestive of persistent disease, defined by the following: normal physical examination; reduction from the peak serum CA-125 level to a normal value of >= 5 U/mL; complete regression of recurrent lesions by CT scan of the abdomen/pelvis No low malignant potential tumors or noninvasive disease GOG performance status 0-1 ANC >= 1,500/mm^3 Platelet count >= 100,000/mm^3 Hemoglobin >= 8.0 g/dL Creatinine =< 1.5 times upper limit of normal (ULN) Bilirubin =< 1.5 times ULN AST =< 2.5 times ULN Alkaline phosphatase =< 2.5 times ULN No known allergy to murine proteins, documented anaphylactic reaction to any drug, or intolerance to cyclophosphamide No active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, or ankylosing spondylitis) No recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia No acquired, hereditary, or congenital immunodeficiencies No other concurrent uncontrolled diseases No contraindications to pressor agents No other invasive malignancies within the past 5 years, except nonmelanoma skin cancer No prior cancer treatment that would contraindicate study therapy No concurrent chronic treatment with immunosuppressive drugs (e.g., cyclosporine, adrenocorticotropic hormone [ACTH], or systemic corticosteroids)

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Robert Edwards

Organizational Affiliation

Gynecologic Oncology Group

Official's Role

Principal Investigator

Facility Information:

Facility Name

Gynecologic Oncology Group

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19103

Country

United States

12. IPD Sharing Statement

Learn more about this trial

We'll reach out to this number within 24 hrs